指南与共识眼底病与葡萄膜炎眼整形与眼眶

冯·希佩尔-林道病眼部监测共识指南

Consensus Guidelines for Ocular Surveillance of von Hippel-Lindau Disease.
指南 / 共识 · Ophthalmology · 2023-12-12

该指南由眼科专家小组通过系统文献综述制定,针对冯·希佩尔-林道(VHL)病患者提出眼部监测与早期干预建议,包括终身周期性筛查、遗传检测、妊娠期监测及及时治疗视网膜血管母细胞瘤等共识条款,证据质量有限且无对照临床试验数据。

要点

  • 已知或疑似VHL病患者应定期进行眼部筛查(证据III级,强度C,共识度2A)。
  • 有VHL病风险者(如一级亲属或单发/多发视网膜血管母细胞瘤患者)应进行基因检测(III/C/2A)。
  • 眼部筛查应从出生后12个月内开始并持续终身,30岁前约每6-12个月一次,之后至少每年一次。

核心结论

  • 基于观察性研究的现有证据,广泛达成共识:对眼部VHL病采取终身监测和早期治疗策略。
  • 该指南得到VHL联盟和国际 ocular oncology 学会的认可,并经美国眼科学会董事会批准。

研究设计与样本

  • 系统文献综述,由视网膜专家和眼部肿瘤专家组成的专家小组制定。
  • 召集VHL病所有器官临床管理专家联盟,眼科分委员会提出问题并进行系统文献综述。
  • 对主题质量和相关性以及每项推荐的强度进行证据分级,制定指南推荐。

主要发现

  • 证据质量有限,无对照临床试验数据可用。
  • 共识指南包括8条推荐,涵盖筛查、基因检测、筛查时间、妊娠监测、影像技术、专科管理及治疗时机。

关键数值与推荐

  • 已知或疑似VHL病患者应定期进行眼部筛查(证据类型III,证据强度C,共识度2A)。
  • 有VHL病风险者,包括已知VHL病患者的一级亲属或任何单发或多灶性视网膜血管母细胞瘤患者,应进行致病性VHL病基因变异的基因检测(III/C/2A)。
  • 眼部筛查应在出生后12个月内开始并持续终身(III/C/2A)。
  • 眼部筛查应大约每6至12个月进行一次直至30岁,之后至少每年一次(III/C-D/2A)。
  • 计划妊娠前应进行眼部筛查,妊娠期间每6至12个月一次(IV/D/2A)。

临床怎么用

  • 已知或疑似VHL病患者应接受定期眼部筛查,从出生后12个月内开始并持续终身。
  • 有VHL病风险者应进行基因检测作为适当医学评估的一部分。
  • 筛查频率:30岁前约每6-12个月一次,之后至少每年一次;计划妊娠前及妊娠期间每6-12个月一次。
  • 超广角彩色眼底摄影和超广角荧光素血管造影可在某些情况下分别用于监测和检测视网膜血管母细胞瘤。
  • 患者应尽可能由具有VHL病或视网膜血管母细胞瘤经验的亚专科医生管理,理想在多学科中心内进行;黄斑外或视盘外视网膜血管母细胞瘤应及时治疗。

局限性

  • 证据质量有限,无对照临床试验数据可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop guidelines for ocular surveillance and early intervention for individuals with von Hippel-Lindau (VHL) disease. DESIGN: Systematic review of the literature. PARTICIPANTS: Expert panel of retina specialists and ocular oncologists. METHODS: A consortium of experts on clinical management of all-organ aspects of VHL disease was convened. Working groups with expertise in organ-specific features of VHL disease were tasked with development of evidence-based guidelines for each organ system. The ophthalmology subcommittee formulated questions for consideration and performed a systematic literature review. Evidence was graded for topic quality and relevance and the strength of each recommendation, and guideline recommendations were developed. RESULTS: The quality of evidence was limited, and no controlled clinical trial data were available. Consensus guidelines included: (1) individuals with known or suspected VHL disease should undergo periodic ocular screening (evidence type, III; evidence strength, C; degree of consensus, 2A); (2) patients at risk of VHL disease, including first-degree relatives of patients with known VHL disease, or any patient with single or multifocal retinal hemangioblastomas (RHs), should undergo genetic testing for pathologic VHL disease gene variants as part of an appropriate medical evaluation (III/C/2A); (3) ocular screening should begin within 12 months after birth and continue throughout life (III/C/2A); (4) ocular screening should occur approximately every 6 to 12 months until 30 years of age and then at least yearly thereafter (III/C-D/2A); (5) ocular screening should be performed before a planned pregnancy and every 6 to 12 months during pregnancy (IV/D/2A); (6) ultra-widefield color fundus photography may be helpful in certain circumstances to monitor RHs, and ultra-widefield fluorescein angiography may be helpful in certain circumstances to detect small RHs (IV/D/2A); (7) patients should be managed, whenever possible, by those with subspecialty training, with experience with VHL disease or RHs, or with both and ideally within the context of a multidisciplinary center capable of providing multiorgan surveillance and access to genetic testing (IV/D/2A); (8) extramacular or extrapapillary RHs should be treated promptly (III/C/2A). CONCLUSIONS: Based on available evidence from observational studies, broad agreement was reached for a strategy of lifelong surveillance and early treatment for ocular VHL disease. These guidelines were endorsed by the VHL Alliance and the International Society of Ocular Oncology and were approved by the American Academy of Ophthalmology Board of Trustees. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Daniels AB, Chang EY, Chew EY, et al. Consensus Guidelines for Ocular Surveillance of von Hippel-Lindau Disease. Ophthalmology. 2023. PMID: 38092079. doi:10.1016/j.ophtha.2023.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。